1 Introduction to Research & Analysis Reports
1.1 Nanostructured Drug Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Nanostructured Drug Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Nanostructured Drug Overall Market Size
2.1 Global Nanostructured Drug Market Size: 2022 VS 2029
2.2 Global Nanostructured Drug Revenue, Prospects & Forecasts: 2018-2029
2.3 Global Nanostructured Drug Sales: 2018-2029
3 Company Landscape
3.1 Top Nanostructured Drug Players in Global Market
3.2 Top Global Nanostructured Drug Companies Ranked by Revenue
3.3 Global Nanostructured Drug Revenue by Companies
3.4 Global Nanostructured Drug Sales by Companies
3.5 Global Nanostructured Drug Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 Nanostructured Drug Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers Nanostructured Drug Product Type
3.8 Tier 1, Tier 2 and Tier 3 Nanostructured Drug Players in Global Market
3.8.1 List of Global Tier 1 Nanostructured Drug Companies
3.8.2 List of Global Tier 2 and Tier 3 Nanostructured Drug Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type – Global Nanostructured Drug Market Size Markets, 2022 & 2029
4.1.2 Liposomes
4.1.3 Polymeric Micelles
4.1.4 Solid lipid Nanoparticles
4.1.5 Microemulsion and Nanoemulsion
4.1.6 Nanosuspension
4.2 By Type – Global Nanostructured Drug Revenue & Forecasts
4.2.1 By Type – Global Nanostructured Drug Revenue, 2018-2023
4.2.2 By Type – Global Nanostructured Drug Revenue, 2024-2029
4.2.3 By Type – Global Nanostructured Drug Revenue Market Share, 2018-2029
4.3 By Type – Global Nanostructured Drug Sales & Forecasts
4.3.1 By Type – Global Nanostructured Drug Sales, 2018-2023
4.3.2 By Type – Global Nanostructured Drug Sales, 2024-2029
4.3.3 By Type – Global Nanostructured Drug Sales Market Share, 2018-2029
4.4 By Type – Global Nanostructured Drug Price (Manufacturers Selling Prices), 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Nanostructured Drug Market Size, 2022 & 2029
5.1.2 Cancer and Tumors
5.1.3 Autoimmune Disorders
5.2 By Application – Global Nanostructured Drug Revenue & Forecasts
5.2.1 By Application – Global Nanostructured Drug Revenue, 2018-2023
5.2.2 By Application – Global Nanostructured Drug Revenue, 2024-2029
5.2.3 By Application – Global Nanostructured Drug Revenue Market Share, 2018-2029
5.3 By Application – Global Nanostructured Drug Sales & Forecasts
5.3.1 By Application – Global Nanostructured Drug Sales, 2018-2023
5.3.2 By Application – Global Nanostructured Drug Sales, 2024-2029
5.3.3 By Application – Global Nanostructured Drug Sales Market Share, 2018-2029
5.4 By Application – Global Nanostructured Drug Price (Manufacturers Selling Prices), 2018-2029
6 Sights by Region
6.1 By Region – Global Nanostructured Drug Market Size, 2022 & 2029
6.2 By Region – Global Nanostructured Drug Revenue & Forecasts
6.2.1 By Region – Global Nanostructured Drug Revenue, 2018-2023
6.2.2 By Region – Global Nanostructured Drug Revenue, 2024-2029
6.2.3 By Region – Global Nanostructured Drug Revenue Market Share, 2018-2029
6.3 By Region – Global Nanostructured Drug Sales & Forecasts
6.3.1 By Region – Global Nanostructured Drug Sales, 2018-2023
6.3.2 By Region – Global Nanostructured Drug Sales, 2024-2029
6.3.3 By Region – Global Nanostructured Drug Sales Market Share, 2018-2029
6.4 North America
6.4.1 By Country – North America Nanostructured Drug Revenue, 2018-2029
6.4.2 By Country – North America Nanostructured Drug Sales, 2018-2029
6.4.3 US Nanostructured Drug Market Size, 2018-2029
6.4.4 Canada Nanostructured Drug Market Size, 2018-2029
6.4.5 Mexico Nanostructured Drug Market Size, 2018-2029
6.5 Europe
6.5.1 By Country – Europe Nanostructured Drug Revenue, 2018-2029
6.5.2 By Country – Europe Nanostructured Drug Sales, 2018-2029
6.5.3 Germany Nanostructured Drug Market Size, 2018-2029
6.5.4 France Nanostructured Drug Market Size, 2018-2029
6.5.5 U.K. Nanostructured Drug Market Size, 2018-2029
6.5.6 Italy Nanostructured Drug Market Size, 2018-2029
6.5.7 Russia Nanostructured Drug Market Size, 2018-2029
6.5.8 Nordic Countries Nanostructured Drug Market Size, 2018-2029
6.5.9 Benelux Nanostructured Drug Market Size, 2018-2029
6.6 Asia
6.6.1 By Region – Asia Nanostructured Drug Revenue, 2018-2029
6.6.2 By Region – Asia Nanostructured Drug Sales, 2018-2029
6.6.3 China Nanostructured Drug Market Size, 2018-2029
6.6.4 Japan Nanostructured Drug Market Size, 2018-2029
6.6.5 South Korea Nanostructured Drug Market Size, 2018-2029
6.6.6 Southeast Asia Nanostructured Drug Market Size, 2018-2029
6.6.7 India Nanostructured Drug Market Size, 2018-2029
6.7 South America
6.7.1 By Country – South America Nanostructured Drug Revenue, 2018-2029
6.7.2 By Country – South America Nanostructured Drug Sales, 2018-2029
6.7.3 Brazil Nanostructured Drug Market Size, 2018-2029
6.7.4 Argentina Nanostructured Drug Market Size, 2018-2029
6.8 Middle East & Africa
6.8.1 By Country – Middle East & Africa Nanostructured Drug Revenue, 2018-2029
6.8.2 By Country – Middle East & Africa Nanostructured Drug Sales, 2018-2029
6.8.3 Turkey Nanostructured Drug Market Size, 2018-2029
6.8.4 Israel Nanostructured Drug Market Size, 2018-2029
6.8.5 Saudi Arabia Nanostructured Drug Market Size, 2018-2029
6.8.6 UAE Nanostructured Drug Market Size, 2018-2029
7 Manufacturers & Brands Profiles
7.1 Merck
7.1.1 Merck Company Summary
7.1.2 Merck Business Overview
7.1.3 Merck Nanostructured Drug Major Product Offerings
7.1.4 Merck Nanostructured Drug Sales and Revenue in Global (2018-2023)
7.1.5 Merck Key News & Latest Developments
7.2 Pfizer
7.2.1 Pfizer Company Summary
7.2.2 Pfizer Business Overview
7.2.3 Pfizer Nanostructured Drug Major Product Offerings
7.2.4 Pfizer Nanostructured Drug Sales and Revenue in Global (2018-2023)
7.2.5 Pfizer Key News & Latest Developments
7.3 Novartis
7.3.1 Novartis Company Summary
7.3.2 Novartis Business Overview
7.3.3 Novartis Nanostructured Drug Major Product Offerings
7.3.4 Novartis Nanostructured Drug Sales and Revenue in Global (2018-2023)
7.3.5 Novartis Key News & Latest Developments
7.4 Abbott
7.4.1 Abbott Company Summary
7.4.2 Abbott Business Overview
7.4.3 Abbott Nanostructured Drug Major Product Offerings
7.4.4 Abbott Nanostructured Drug Sales and Revenue in Global (2018-2023)
7.4.5 Abbott Key News & Latest Developments
7.5 GlaxoSmithKline
7.5.1 GlaxoSmithKline Company Summary
7.5.2 GlaxoSmithKline Business Overview
7.5.3 GlaxoSmithKline Nanostructured Drug Major Product Offerings
7.5.4 GlaxoSmithKline Nanostructured Drug Sales and Revenue in Global (2018-2023)
7.5.5 GlaxoSmithKline Key News & Latest Developments
7.6 Roche
7.6.1 Roche Company Summary
7.6.2 Roche Business Overview
7.6.3 Roche Nanostructured Drug Major Product Offerings
7.6.4 Roche Nanostructured Drug Sales and Revenue in Global (2018-2023)
7.6.5 Roche Key News & Latest Developments
7.7 Sanofi
7.7.1 Sanofi Company Summary
7.7.2 Sanofi Business Overview
7.7.3 Sanofi Nanostructured Drug Major Product Offerings
7.7.4 Sanofi Nanostructured Drug Sales and Revenue in Global (2018-2023)
7.7.5 Sanofi Key News & Latest Developments
7.8 Eli Lilly
7.8.1 Eli Lilly Company Summary
7.8.2 Eli Lilly Business Overview
7.8.3 Eli Lilly Nanostructured Drug Major Product Offerings
7.8.4 Eli Lilly Nanostructured Drug Sales and Revenue in Global (2018-2023)
7.8.5 Eli Lilly Key News & Latest Developments
7.9 Astrazeneca
7.9.1 Astrazeneca Company Summary
7.9.2 Astrazeneca Business Overview
7.9.3 Astrazeneca Nanostructured Drug Major Product Offerings
7.9.4 Astrazeneca Nanostructured Drug Sales and Revenue in Global (2018-2023)
7.9.5 Astrazeneca Key News & Latest Developments
7.10 Johnson & Johnson
7.10.1 Johnson & Johnson Company Summary
7.10.2 Johnson & Johnson Business Overview
7.10.3 Johnson & Johnson Nanostructured Drug Major Product Offerings
7.10.4 Johnson & Johnson Nanostructured Drug Sales and Revenue in Global (2018-2023)
7.10.5 Johnson & Johnson Key News & Latest Developments
7.11 Celgene
7.11.1 Celgene Company Summary
7.11.2 Celgene Nanostructured Drug Business Overview
7.11.3 Celgene Nanostructured Drug Major Product Offerings
7.11.4 Celgene Nanostructured Drug Sales and Revenue in Global (2018-2023)
7.11.5 Celgene Key News & Latest Developments
7.12 Novavax
7.12.1 Novavax Company Summary
7.12.2 Novavax Nanostructured Drug Business Overview
7.12.3 Novavax Nanostructured Drug Major Product Offerings
7.12.4 Novavax Nanostructured Drug Sales and Revenue in Global (2018-2023)
7.12.5 Novavax Key News & Latest Developments
7.13 Stryker
7.13.1 Stryker Company Summary
7.13.2 Stryker Nanostructured Drug Business Overview
7.13.3 Stryker Nanostructured Drug Major Product Offerings
7.13.4 Stryker Nanostructured Drug Sales and Revenue in Global (2018-2023)
7.13.5 Stryker Key News & Latest Developments
7.14 Gilead Sciences
7.14.1 Gilead Sciences Company Summary
7.14.2 Gilead Sciences Business Overview
7.14.3 Gilead Sciences Nanostructured Drug Major Product Offerings
7.14.4 Gilead Sciences Nanostructured Drug Sales and Revenue in Global (2018-2023)
7.14.5 Gilead Sciences Key News & Latest Developments
7.15 OSI Pharmaceuticals
7.15.1 OSI Pharmaceuticals Company Summary
7.15.2 OSI Pharmaceuticals Business Overview
7.15.3 OSI Pharmaceuticals Nanostructured Drug Major Product Offerings
7.15.4 OSI Pharmaceuticals Nanostructured Drug Sales and Revenue in Global (2018-2023)
7.15.5 OSI Pharmaceuticals Key News & Latest Developments
7.16 Kadmon Pharmaceuticals
7.16.1 Kadmon Pharmaceuticals Company Summary
7.16.2 Kadmon Pharmaceuticals Business Overview
7.16.3 Kadmon Pharmaceuticals Nanostructured Drug Major Product Offerings
7.16.4 Kadmon Pharmaceuticals Nanostructured Drug Sales and Revenue in Global (2018-2023)
7.16.5 Kadmon Pharmaceuticals Key News & Latest Developments
7.17 Samyang Biopharm
7.17.1 Samyang Biopharm Company Summary
7.17.2 Samyang Biopharm Business Overview
7.17.3 Samyang Biopharm Nanostructured Drug Major Product Offerings
7.17.4 Samyang Biopharm Nanostructured Drug Sales and Revenue in Global (2018-2023)
7.17.5 Samyang Biopharm Key News & Latest Developments
7.18 Mitsubishi Pharma
7.18.1 Mitsubishi Pharma Company Summary
7.18.2 Mitsubishi Pharma Business Overview
7.18.3 Mitsubishi Pharma Nanostructured Drug Major Product Offerings
7.18.4 Mitsubishi Pharma Nanostructured Drug Sales and Revenue in Global (2018-2023)
7.18.5 Mitsubishi Pharma Key News & Latest Developments
7.19 Kaken Pharmaceutical
7.19.1 Kaken Pharmaceutical Company Summary
7.19.2 Kaken Pharmaceutical Business Overview
7.19.3 Kaken Pharmaceutical Nanostructured Drug Major Product Offerings
7.19.4 Kaken Pharmaceutical Nanostructured Drug Sales and Revenue in Global (2018-2023)
7.19.5 Kaken Pharmaceutical Key News & Latest Developments
7.20 Selecta Biosciences
7.20.1 Selecta Biosciences Company Summary
7.20.2 Selecta Biosciences Business Overview
7.20.3 Selecta Biosciences Nanostructured Drug Major Product Offerings
7.20.4 Selecta Biosciences Nanostructured Drug Sales and Revenue in Global (2018-2023)
7.20.5 Selecta Biosciences Key News & Latest Developments
7.21 Par Pharmaceutical
7.21.1 Par Pharmaceutical Company Summary
7.21.2 Par Pharmaceutical Business Overview
7.21.3 Par Pharmaceutical Nanostructured Drug Major Product Offerings
7.21.4 Par Pharmaceutical Nanostructured Drug Sales and Revenue in Global (2018-2023)
7.21.5 Par Pharmaceutical Key News & Latest Developments
7.22 Cerulean Pharma
7.22.1 Cerulean Pharma Company Summary
7.22.2 Cerulean Pharma Business Overview
7.22.3 Cerulean Pharma Nanostructured Drug Major Product Offerings
7.22.4 Cerulean Pharma Nanostructured Drug Sales and Revenue in Global (2018-2023)
7.22.5 Cerulean Pharma Key News & Latest Developments
7.23 Navidea Biopharmaceuticals
7.23.1 Navidea Biopharmaceuticals Company Summary
7.23.2 Navidea Biopharmaceuticals Business Overview
7.23.3 Navidea Biopharmaceuticals Nanostructured Drug Major Product Offerings
7.23.4 Navidea Biopharmaceuticals Nanostructured Drug Sales and Revenue in Global (2018-2023)
7.23.5 Navidea Biopharmaceuticals Key News & Latest Developments
7.24 Lummy
7.24.1 Lummy Company Summary
7.24.2 Lummy Business Overview
7.24.3 Lummy Nanostructured Drug Major Product Offerings
7.24.4 Lummy Nanostructured Drug Sales and Revenue in Global (2018-2023)
7.24.5 Lummy Key News & Latest Developments
8 Global Nanostructured Drug Production Capacity, Analysis
8.1 Global Nanostructured Drug Production Capacity, 2018-2029
8.2 Nanostructured Drug Production Capacity of Key Manufacturers in Global Market
8.3 Global Nanostructured Drug Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Nanostructured Drug Supply Chain Analysis
10.1 Nanostructured Drug Industry Value Chain
10.2 Nanostructured Drug Upstream Market
10.3 Nanostructured Drug Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Nanostructured Drug Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer
世界のナノ構造薬剤市場予測2023-2029：リポソーム、高分子ミセル、固体脂質ナノ粒子、マイクロエマルション・ナノエマルション、ナノサスペンション |
| 【英語タイトル】Nanostructured Drug Market, Global Outlook and Forecast 2023-2029 | |
 | ・商品コード：MMG23JU5796 ・発行会社（調査会社）：Market Monitor Global ・発行日：2023年6月 ・ページ数：122 ・レポート言語：英語 ・レポート形式：PDF ・納品方法：Eメール（受注後2-3営業日） ・調査対象地域：グローバル、北米、アメリカ、ヨーロッパ、アジア、日本、中国、東南アジア、インド、南米、中東・アフリカなど ・産業分野：医薬品＆医療 |
| Single User（1名様閲覧用） | USD3,250 ⇒換算￥494,000 | 見積依頼/購入/質問フォーム |
| Multi User（20名様閲覧用） | USD4,225 ⇒換算￥642,200 | 見積依頼/購入/質問フォーム |
| Enterprise User（閲覧人数制限なし） | USD4,875 ⇒換算￥741,000 | 見積依頼/購入/質問フォーム |
|
※販売価格オプションの説明 ※お支払金額：換算金額（日本円）＋消費税 ※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡） ※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能） |
| 当調査レポートは次の情報を含め、世界のナノ構造薬剤市場規模と予測を収録しています。・世界のナノ構造薬剤市場：売上、2018年-2023年、2024年-2029年 ・世界のナノ構造薬剤市場：販売量、2018年-2023年、2024年-2029年 ・世界のトップ5企業、2022年 世界のナノ構造薬剤市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「リポソーム」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。 ナノ構造薬剤のグローバル主要企業は、Merck、 Pfizer、 Novartis、 Abbott、 GlaxoSmithKline、 Roche、 Sanofi、 Eli Lilly、 Astrazeneca、 Johnson & Johnson、 Celgene、 Novavax、 Stryker、 Gilead Sciences、 OSI Pharmaceuticals、 Kadmon Pharmaceuticals、 Samyang Biopharm、 Mitsubishi Pharma、 Kaken Pharmaceutical、 Selecta Biosciences、 Par Pharmaceutical、 Cerulean Pharma、 Navidea Biopharmaceuticals、 Lummyなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。 MARKET MONITOR GLOBAL（MMG）は、ナノ構造薬剤のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。 【セグメント別市場分析】 世界のナノ構造薬剤市場：タイプ別、2018年-2023年、2024年-2029年 世界のナノ構造薬剤市場：タイプ別市場シェア、2022年 ・リポソーム、高分子ミセル、固体脂質ナノ粒子、マイクロエマルション・ナノエマルション、ナノサスペンション 世界のナノ構造薬剤市場：用途別、2018年-2023年、2024年-2029年 世界のナノ構造薬剤市場：用途別市場シェア、2022年 ・がん・腫瘍、自己免疫疾患 世界のナノ構造薬剤市場：地域・国別、2018年-2023年、2024年-2029年 世界のナノ構造薬剤市場：地域別市場シェア、2022年 ・北米：アメリカ、カナダ、メキシコ ・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア ・アジア：中国、日本、韓国、東南アジア、インド ・南米：ブラジル、アルゼンチン ・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE 【競合分析】 また、当レポートは主要な市場参加者の分析を提供します。 ・主要企業におけるナノ構造薬剤のグローバル売上、2018年-2023年 ・主要企業におけるナノ構造薬剤のグローバル売上シェア、2022年 ・主要企業におけるナノ構造薬剤のグローバル販売量、2018年-2023年 ・主要企業におけるナノ構造薬剤のグローバル販売量シェア、2022年 さらに、当レポートは主要企業のプロファイルを提示します。 Merck、 Pfizer、 Novartis、 Abbott、 GlaxoSmithKline、 Roche、 Sanofi、 Eli Lilly、 Astrazeneca、 Johnson & Johnson、 Celgene、 Novavax、 Stryker、 Gilead Sciences、 OSI Pharmaceuticals、 Kadmon Pharmaceuticals、 Samyang Biopharm、 Mitsubishi Pharma、 Kaken Pharmaceutical、 Selecta Biosciences、 Par Pharmaceutical、 Cerulean Pharma、 Navidea Biopharmaceuticals、 Lummy ************************************************************* ・調査・分析レポートの概要 ナノ構造薬剤市場の定義 市場セグメント 世界のナノ構造薬剤市場概要 当レポートの特徴・ベネフィット 調査手法と情報源 ・世界のナノ構造薬剤市場規模 世界のナノ構造薬剤市場規模：2022年 VS 2029年 世界のナノ構造薬剤市場規模と予測 2018年-2029年 ・競争状況 グローバルトップ企業 売上ベースでのグローバルトップ企業 企業別グローバルでのナノ構造薬剤の売上 グローバルトップ3およびトップ5企業、2022年売上ベース グローバル企業のナノ構造薬剤製品タイプ グローバルにおけるティア1、ティア2、ティア3企業 ・タイプ別市場分析 タイプ区分：リポソーム、高分子ミセル、固体脂質ナノ粒子、マイクロエマルション・ナノエマルション、ナノサスペンション ナノ構造薬剤のタイプ別グローバル売上・予測 ・用途別市場分析 用途区分：がん・腫瘍、自己免疫疾患 ナノ構造薬剤の用途別グローバル売上・予測 ・地域別市場分析 地域別ナノ構造薬剤市場規模 2022年と2029年 地域別ナノ構造薬剤売上・予測 北米市場：アメリカ、カナダ、メキシコ ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア アジア市場：中国、日本、韓国、東南アジア、インド 南米市場：ブラジル、アルゼンチン 中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE ・主要企業のプロファイル（企業概要、事業概要、主要製品、売上、ニュースなど） Merck、 Pfizer、 Novartis、 Abbott、 GlaxoSmithKline、 Roche、 Sanofi、 Eli Lilly、 Astrazeneca、 Johnson & Johnson、 Celgene、 Novavax、 Stryker、 Gilead Sciences、 OSI Pharmaceuticals、 Kadmon Pharmaceuticals、 Samyang Biopharm、 Mitsubishi Pharma、 Kaken Pharmaceutical、 Selecta Biosciences、 Par Pharmaceutical、 Cerulean Pharma、 Navidea Biopharmaceuticals、 Lummy ... |
This report aims to provide a comprehensive presentation of the global market for Nanostructured Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Nanostructured Drug. This report contains market size and forecasts of Nanostructured Drug in global, including the following market information:
Global Nanostructured Drug Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global Nanostructured Drug Market Sales, 2018-2023, 2024-2029, (K MT)
Global top five Nanostructured Drug companies in 2022 (%)
The global Nanostructured Drug market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million.
Liposomes Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Nanostructured Drug include Merck, Pfizer, Novartis, Abbott, GlaxoSmithKline, Roche, Sanofi, Eli Lilly and Astrazeneca, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Nanostructured Drug manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Nanostructured Drug Market, by Type, 2018-2023, 2024-2029 ($ Millions) & (K MT)
Global Nanostructured Drug Market Segment Percentages, by Type, 2022 (%)
Liposomes
Polymeric Micelles
Solid lipid Nanoparticles
Microemulsion and Nanoemulsion
Nanosuspension
Global Nanostructured Drug Market, by Application, 2018-2023, 2024-2029 ($ Millions) & (K MT)
Global Nanostructured Drug Market Segment Percentages, by Application, 2022 (%)
Cancer and Tumors
Autoimmune Disorders
Global Nanostructured Drug Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions) & (K MT)
Global Nanostructured Drug Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Nanostructured Drug revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Nanostructured Drug revenues share in global market, 2022 (%)
Key companies Nanostructured Drug sales in global market, 2018-2023 (Estimated), (K MT)
Key companies Nanostructured Drug sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Merck
Pfizer
Novartis
Abbott
GlaxoSmithKline
Roche
Sanofi
Eli Lilly
Astrazeneca
Johnson & Johnson
Celgene
Novavax
Stryker
Gilead Sciences
OSI Pharmaceuticals
Kadmon Pharmaceuticals
Samyang Biopharm
Mitsubishi Pharma
Kaken Pharmaceutical
Selecta Biosciences
Par Pharmaceutical
Cerulean Pharma
Navidea Biopharmaceuticals
Lummy
Outline of Major Chapters:
Chapter 1: Introduces the definition of Nanostructured Drug, market overview.
Chapter 2: Global Nanostructured Drug market size in revenue and volume.
Chapter 3: Detailed analysis of Nanostructured Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Nanostructured Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Nanostructured Drug capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.
❖ レポートの目次 ❖
| ★調査レポート[世界のナノ構造薬剤市場予測2023-2029：リポソーム、高分子ミセル、固体脂質ナノ粒子、マイクロエマルション・ナノエマルション、ナノサスペンション] (コード：MMG23JU5796)販売に関する免責事項を必ずご確認ください。 |
| ★調査レポート[世界のナノ構造薬剤市場予測2023-2029：リポソーム、高分子ミセル、固体脂質ナノ粒子、マイクロエマルション・ナノエマルション、ナノサスペンション]についてメールでお問い合わせ |
